Temozolomide Oral Product

DRUG3 trials

Sponsors

Grupo Español de Investigación en Neurooncología, John Flickinger, Abramson Cancer Center at Penn Medicine

Conditions

GlioblastomaNeuroendocrine Tumor Grade 2Neuroendocrine Tumors

Phase 1

TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma

CompletedNCT03529448

Grupo Español de Investigación en NeurooncologíaGlioblastoma

Start: 2023-08-18End: 2025-11-13Updated: 2026-02-12

Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma

Active, not recruitingNCT04019262

John FlickingerGlioblastoma

Start: 2021-12-14End: 2027-07-31Updated: 2025-06-18

Phase 2

CapTemY90 for Grade 2/3 NET Liver Metastases

RecruitingNCT04339036

Abramson Cancer Center at Penn MedicineNeuroendocrine Tumor Grade 2, Neuroendocrine Tumors

Start: 2021-10-07End: 2026-05-01Target: 70Updated: 2025-12-10

Related Papers

ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs).

2022-07-201 citations